The trial is taking place at:
H

Hospital Universitario Virgen de la Victoria | Cardiology Department

Veeva-enabled site

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer (CYCLONE 2)

Lilly logo

Lilly

Status and phase

Active, not recruiting
Phase 3
Phase 2

Conditions

Prostate Cancer

Treatments

Drug: Abiraterone Acetate
Drug: Placebo
Drug: Abemaciclib
Drug: Prednisone

Study type

Interventional

Funder types

Industry

Identifiers

NCT03706365
2016-004276-21 (EudraCT Number)
16598
I3Y-MC-JPCM (Other Identifier)

Details and patient eligibility

About

This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.

Enrollment

350 estimated patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* Histologically confirmed adenocarcinoma of the prostate. * Metastatic prostate cancer documented by positive bone scan and/or measurable soft tissue metastatic lesions by CT or magnetic resonance imaging (MRI). * Progressive disease at study entry demonstrated during continuous androgen-deprivation therapy (ADT)/post orchiectomy defined as one or more of the following: * PSA progression * Radiographic progression per Response Evaluation Criteria in Solid Tumors (RECIST)1.1 for soft tissue and/or per Prostate Cancer Working Group 3 (PCWG3) for bone, with or without PSA progression * Have adequate organ function. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.

Exclusion criteria

* Prior therapy with cytochrome P450 (CYP)17 inhibitors. * Prior treatment with abemaciclib or any cyclin-dependent kinase (CDK) 4 \& 6 inhibitors. * Prior cytotoxic chemotherapy for metastatic castration resistant prostate cancer (participants treated with docetaxel in the metastatic hormone-sensitive prostate cancer \[mHSPC\] are eligible). Prior radiopharmaceuticals for prostate cancer, or prior enzalutamide, apalutamide, darolutamide or sipuleucel-T. Participants who had prior radiation or surgery to all target lesions. * Currently enrolled in a clinical study involving an investigational product. * Gastrointestinal disorder affecting the absorption or ability to swallow large pills. * Clinically significant heart disease, active or chronic liver disease, moderate/severe hepatic impairment (Child-Pugh Class B and C).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

350 participants in 6 patient groups

A1. Abiraterone plus Prednisone and Abemaciclib
Experimental group
Description:
Abiraterone plus prednisone administered orally and abemaciclib administered orally.
Treatment:
Drug: Prednisone
Drug: Abemaciclib
Drug: Abiraterone Acetate
A2. Abiraterone plus Prednisone and Abemaciclib
Experimental group
Description:
Abiraterone plus prednisone administered orally and abemaciclib administered orally.
Treatment:
Drug: Prednisone
Drug: Abemaciclib
Drug: Abiraterone Acetate
B1. Abiraterone plus Prednisone and Placebo
Active Comparator group
Description:
Abiraterone plus prednisone administered orally and placebo administered orally.
Treatment:
Drug: Prednisone
Drug: Placebo
Drug: Abiraterone Acetate
B2. Abiraterone plus Prednisone and Placebo
Active Comparator group
Description:
Abiraterone plus prednisone administered orally and placebo administered orally.
Treatment:
Drug: Prednisone
Drug: Placebo
Drug: Abiraterone Acetate
A. Abiraterone plus Prednisone and Abemaciclib
Experimental group
Description:
Abiraterone plus prednisone administered orally and abemaciclib administered orally.
Treatment:
Drug: Prednisone
Drug: Abemaciclib
Drug: Abiraterone Acetate
B. Abiraterone plus Prednisone and Placebo
Active Comparator group
Description:
Abiraterone plus prednisone administered orally and placebo administered orally.
Treatment:
Drug: Prednisone
Drug: Placebo
Drug: Abiraterone Acetate

Trial contacts and locations

106

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems